IL6R and autoimmune disease: To date, clinically available antibodies targeting the IL-6/IL-6R/JAK pathway include anti-IL-6 antibodies (e.g., siltuximab), anti-IL-6R antibodies (e.g., tocilizumab and sarilumab), and anti-JAK antibodies (e.g., ruxolitinib and baricitinib), all of which have been successfully used to treat autoimmune diseases such as rheumatoid arthritis.